Steven Lydeamore, CEO of Immuron, presenting at Coffee Microcaps – Immuron…

Steven Lydeamore, CEO of Immuron, presenting at Coffee Microcaps – Immuron…


MELBOURNE, Australia, May 02, 2023 (GLOBE NEWSWIRE) — Immuron Limited (IMCIMRNan Australia-based and globally integrated biopharmaceutical company that has developed two commercial oral immunotherapeutics for the treatment of enteric diseases, is pleased to provide a copy of the presentation made by our Chief Executive Officer at the Coffee Microcaps Conference in Melbourne today. Steven Lydeamore.

A copy of the presentation slide is available on the company’s website.

This press release has been authorized by the directors of Immuron Limited.


Steven Lydeamore
Managing Director
Telephone: +61 (0)3 9824 5254

About Travelan®
Travelan® is an orally administered passive immunotherapy that prophylactically reduces the chance of developing travelers’ diarrhea, a digestive tract disease commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a highly purified tablet formulation of bovine hyperimmune antibodies and other factors that, when taken with meals, bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers’ diarrhea. Travelan in Australia® is a drug listed on the Australian Register for Therapeutic Goods (AUST L 106709) and is said to reduce the risk of travelers’ diarrhea and mild gastrointestinal disorders and is antimicrobial. In Canada Travelan® is a licensed natural health product (NPN 80046016) and is thought to reduce the risk of travelers’ diarrhea. Travelan in the US® is sold as a dietary supplement to protect the digestive tract.

About Traveler’s Diarrhea
Traveler’s diarrhea is a gastrointestinal infection with symptoms that include liquid, watery (and occasionally bloody) stools, abdominal cramps, bloating, and fever. Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic ones

Source story

More to explorer